Press Release

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *